EU commission approves Intuniv (guanfacine hydrochloride prolonged release) to treat ADHD- Shire
Shire announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant Intuniv (guanfacine hydrochloride prolonged release tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Comment: Intuniv, a once a day drug, is seen as a non-stimulant and directed to children with ADHD for whom stimulants are unsuitable.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins